---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-174982"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:15:35.714700+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PepGen completes dosing in 15 mg/kg cohort of FREEDOM-DM1; net loss narrows to $23.1M

## Summary
- On track to report topline safety and splicing data from 15 mg/kg cohort in early Q4 2025.
- Concluding FREEDOM trial after 15 mg/kg cohort; transitioning sites to Phase 2 MAD study FREEDOM2-DM1.
- Cash $74.7M sufficient into Q2 2026; net loss $23.1M ($0.70/sh) vs $28.3M ($0.87/sh) YoY.
- Appointed Kasra Kasraian, PhD, as Chief Technology Officer in May 2025.
- FREEDOM2 5 mg/kg cohort results expected Q1 2026.

## SEC filing metadata
- accession: 0001193125-25-174982
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000119312525174982/0001193125-25-174982-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000119312525174982/pepg-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-174982
- JSON: https://secwatch.observer/filing/0001193125-25-174982.json
- Plain text: https://secwatch.observer/filing/0001193125-25-174982.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.